PL1713480T3 - Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych - Google Patents

Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych

Info

Publication number: PL1713480T3
Authority: PL; Poland
Prior art keywords: pyridinium salts; quaternary pyridinium; vasoprotective agents; vasoprotective; agents
Prior art date: 2004-01-12

Application number

PL05726215T

Other languages

English (en)

Inventor

Jerzy Gębicki

Stefan Chłopicki

Original Assignee

Pharmena Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-12

Filing date

2005-01-07

Publication date

2011-12-30

2005-01-07 Application filed by Pharmena Sa filed Critical Pharmena Sa

2011-12-30 Publication of PL1713480T3 publication Critical patent/PL1713480T3/pl

Links

JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 2
230000002666 vasoprotective effect Effects 0.000 title abstract 2
101710129448 Glucose-6-phosphate isomerase 2 Proteins 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004064 dysfunction Effects 0.000 abstract 1
230000003511 endothelial effect Effects 0.000 abstract 1
210000003989 endothelium vascular Anatomy 0.000 abstract 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 abstract 1
229960001123 epoprostenol Drugs 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
230000036542 oxidative stress Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Pulmonology (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Physiology (AREA)
Surgery (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)

PL05726215T 2004-01-12 2005-01-07 Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych PL1713480T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PL04364348A PL364348A1 (pl)	2004-01-12	2004-01-12	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
EP05726215A EP1713480B1 (en)	2004-01-12	2005-01-07	The use of quaternary pyridinium salts as vasoprotective agents
PCT/EP2005/050057 WO2005067927A2 (en)	2004-01-12	2005-01-07	The use of quaternary pyridinium salts as vasoprotective agents

Publications (1)

Publication Number	Publication Date
PL1713480T3 true PL1713480T3 (pl)	2011-12-30

Family

ID=34793495

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04364348A PL364348A1 (pl)	2004-01-12	2004-01-12	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
PL05726215T PL1713480T3 (pl)	2004-01-12	2005-01-07	Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04364348A PL364348A1 (pl)	2004-01-12	2004-01-12	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego

Country Status (13)

Country	Link
US (6)	US7935717B2 (pl)
EP (2)	EP2279738A1 (pl)
JP (2)	JP5052138B2 (pl)
CN (1)	CN1905875B (pl)
AT (1)	ATE524179T1 (pl)
AU (1)	AU2005205066C1 (pl)
CA (1)	CA2547234C (pl)
DK (1)	DK1713480T3 (pl)
ES (1)	ES2372756T3 (pl)
PL (2)	PL364348A1 (pl)
PT (1)	PT1713480E (pl)
RU (1)	RU2366420C2 (pl)
WO (1)	WO2005067927A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL364348A1 (pl)	2004-01-12	2005-07-25	PHARMENA Sp.z o.o.	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
AU2006329564A1 (en)	2005-07-11	2007-07-05	Pharmena North America Inc.	Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP1963270B1 (en) *	2005-12-09	2009-08-05	Cerecon AG	Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
CA2657606A1 (en)	2006-03-08	2007-09-13	Cortria Corporation	Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
CA2700585A1 (en) *	2006-10-18	2008-08-14	Dermena North America, Inc.	Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl)	2007-02-28	2008-09-01	Trigendo Spółka Z Ograniczoną Odpowiedzialnością	Zastosowanie związków pirydyniowych i sposób leczenia
WO2009042440A1 (en) *	2007-09-28	2009-04-02	Cortria Corporation	1-methyl nicotinamide and derivatives for treatment of gastric injury
PL2211858T3 (pl)	2007-10-12	2015-06-30	Politechnika Lodzka	Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
US8304439B1 (en)	2007-10-12	2012-11-06	Politechnika Lodzka	Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
WO2009047290A1 (en) *	2007-10-12	2009-04-16	Politechnika Lodzka	Use of quaternary pyridinium salts for radioprotection
US20110263659A1 (en) *	2008-05-06	2011-10-27	Cortria Corporation	Analogs of 1-Methylnicotinamide
WO2010000673A1 (en) *	2008-07-01	2010-01-07	Politechnika Lódzka	N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US8575175B2 (en)	2008-07-23	2013-11-05	Toray Industries, Inc.	Therapeutic agent for chronic renal failure
EP2186419A1 (en) *	2008-11-13	2010-05-19	Tchibo GmbH	NMP-containing extract, a method of its production and uses thereof
RU2425672C1 (ru) *	2010-04-12	2011-08-10	Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию"	Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
KR101309576B1 (ko) *	2011-05-25	2013-09-17	연세대학교 산학협력단	대사물질을 이용한 심부전 바이오마커
PL226999B1 (pl) *	2013-06-11	2017-10-31	Univ Jagiellonski	Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie
CN105771005A (zh) *	2016-03-24	2016-07-20	乐普（北京）医疗器械股份有限公司	一种抗风湿性血管狭窄药物支架及其制备方法和应用
WO2018015862A1 (en)	2016-07-18	2018-01-25	Pharmena S.A.	1-methylnicotinamide salts for use in raising the blood levels of adiponectin
ES2967074T3 (es) *	2016-07-18	2024-04-25	Pharmena S A	1 metilnicotinamida para el tratamiento de una enfermedad cardiovascular
CN118221546A (zh) *	2017-07-27	2024-06-21	密歇根大学董事会	纤维蛋白溶酶原活化物抑制因子-1（pai-1）抑制剂和使用方法
PL238932B1 (pl) *	2017-12-31	2021-10-18	Univ Jagiellonski	Pochodne soli pirydyniowych oraz ich zastosowanie
PH12021551394B1 (en) *	2019-01-02	2024-04-26	Celagenex Res India Pvt Ltd	Potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function
WO2021205341A1 (en)	2020-04-07	2021-10-14	Pharmena S.A.	1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
EP4213821A2 (en) *	2020-09-21	2023-07-26	The Regents of the University of California	Immunological effects of metabolites
CN115837023B (zh) *	2023-02-20	2023-05-16	中山大学附属第八医院（深圳福田）	1-甲基烟酰胺在制备抗血管钙化药物中的应用
US20240350475A1 (en) *	2023-04-13	2024-10-24	University Of South Carolina	Trigonelline mitigates cardiomyopathy caused by sars-cov-2 spike protein under obesity
PL447656A1 (pl) *	2024-01-31	2025-08-04	Politechnika Poznańska	Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL248942B1 (pl) *	2024-01-31	2026-02-16	Politechnika Poznanska	Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące
PL449092A1 (pl) *	2024-07-01	2026-01-05	Uniwersytet Jagielloński	Synergiczna kombinacja 1-metylonikotynamidu (MNA) i witaminy K do zastosowania w leczeniu lub zapobieganiu powikłaniom sercowo-naczyniowym terapii przeciwnowotworowych
PL450543A1 (pl) *	2024-12-11	2026-06-15	Politechnika Poznańska	Czwartorzędowe sole amoniowe z kationem 3-karbamoilo-1-alkilopirydyniowym i anionem (R)-migdalanowym, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL450542A1 (pl) *	2024-12-11	2026-06-15	Politechnika Poznańska	Czwartorzędowe sole amoniowe zawierające kation 3-karbamoiIo-1-alkilopirydyniowy i anion 4- aminobenzoesanowy, sposób ich otrzymywania i zastosowanie jako środki bakteriobójcze
PL450544A1 (pl) *	2024-12-11	2026-06-15	Politechnika Poznańska	Czwartorzędowe sole amoniowe z kationem 3-karbamoilo-1-alkilopirydyniowym i anionem (S)-migdalanowym, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL452423A1 (pl) *	2025-06-20	2026-08-03	Politechnika Poznańska	Sposób określania właściwości przeciwzapalnych czwartorzędowych soli amoniowych zawierających kation 3-karbamoilo-1-alkilopirydyniowy i anion 4-aminobenzoesanowy z użyciem albuminy jaja kurzego
PL452422A1 (pl) *	2025-06-20	2026-08-03	Politechnika Poznańska	Sposób określania właściwości przeciwzapalnych czwartorzędowych soli amoniowych zawierających anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy z użyciem albuminy jaja kurzego

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE840698C (de) *	1949-07-12	1952-06-05	Cilag Aktiengesellschaft	Verfahren zur herstellung neuer derivate des nicotinsaureamids
GB675430A (en)	1949-07-12	1952-07-09	Cilag Ltd	Novel quaternary nicotinic acid amide derivatives and production thereof
US5260305A (en) *	1988-12-12	1993-11-09	E. R. Squibb & Sons, Inc.	Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US20060263428A1 (en) *	1993-09-20	2006-11-23	Eugenio Cefali	Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) *	1993-09-20	2004-06-08	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) *	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) *	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6406715B1 (en) *	1993-09-20	2002-06-18	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6129930A (en) *	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20030161880A1 (en) *	1997-03-06	2003-08-28	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20010006644A1 (en)	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) *	1997-07-31	2002-10-22	Eugenio A. Cefali	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
IE970731A1 (en) *	1997-10-07	2000-10-04	Fuisz Internat Ltd	Product and method for the treatment of hyperlipidemia
PL190755B1 (pl) *	1999-01-07	2006-01-31	Pharmena Sp Z Oo	Preparat do leczenia i profilaktyki chorób skóry
JP2002255846A (ja) *	2001-02-26	2002-09-11	Sunstar Inc	経口組成物
US20050130990A1 (en) *	2001-03-23	2005-06-16	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) *	2001-03-23	2002-09-23	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US8039459B2 (en) *	2004-07-15	2011-10-18	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US7153870B2 (en) *	2003-07-25	2006-12-26	Pfizer Inc.	Nicotinamide derivatives useful as PDE4 inhibitors
PL364348A1 (pl)	2004-01-12	2005-07-25	PHARMENA Sp.z o.o.	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
EP1811996A1 (en)	2004-11-05	2007-08-01	Arena Pharmaceuticals, Inc.	Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
AU2006329564A1 (en)	2005-07-11	2007-07-05	Pharmena North America Inc.	Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
CA2700585A1 (en)	2006-10-18	2008-08-14	Dermena North America, Inc.	Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl) *	2007-02-28	2008-09-01	Trigendo Spółka Z Ograniczoną Odpowiedzialnością	Zastosowanie związków pirydyniowych i sposób leczenia

2004
- 2004-01-12 PL PL04364348A patent/PL364348A1/pl unknown
2005
- 2005-01-07 AU AU2005205066A patent/AU2005205066C1/en not_active Expired
- 2005-01-07 WO PCT/EP2005/050057 patent/WO2005067927A2/en not_active Ceased
- 2005-01-07 US US10/585,892 patent/US7935717B2/en active Active
- 2005-01-07 JP JP2006548308A patent/JP5052138B2/ja not_active Expired - Lifetime
- 2005-01-07 PT PT05726215T patent/PT1713480E/pt unknown
- 2005-01-07 CN CN2005800017124A patent/CN1905875B/zh not_active Expired - Lifetime
- 2005-01-07 ES ES05726215T patent/ES2372756T3/es not_active Expired - Lifetime
- 2005-01-07 AT AT05726215T patent/ATE524179T1/de active
- 2005-01-07 PL PL05726215T patent/PL1713480T3/pl unknown
- 2005-01-07 RU RU2006129299/15A patent/RU2366420C2/ru active
- 2005-01-07 EP EP10180501A patent/EP2279738A1/en not_active Withdrawn
- 2005-01-07 EP EP05726215A patent/EP1713480B1/en not_active Expired - Lifetime
- 2005-01-07 DK DK05726215.6T patent/DK1713480T3/da active
- 2005-01-07 CA CA2547234A patent/CA2547234C/en not_active Expired - Lifetime
2010
- 2010-01-11 US US12/685,377 patent/US8124631B2/en not_active Expired - Lifetime
2011
- 2011-04-08 US US13/083,106 patent/US8969391B2/en active Active
- 2011-10-24 JP JP2011233155A patent/JP5597179B2/ja not_active Expired - Lifetime
2014
- 2014-06-12 US US14/303,054 patent/US9119844B2/en not_active Expired - Lifetime
2015
- 2015-01-16 US US14/598,888 patent/US9333196B2/en not_active Expired - Lifetime
2016
- 2016-05-04 US US15/146,485 patent/US9675601B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO2005067927A2 (en)	2005-07-28
CA2547234A1 (en)	2005-07-28
US8124631B2 (en)	2012-02-28
RU2006129299A (ru)	2008-02-20
US9333196B2 (en)	2016-05-10
JP5052138B2 (ja)	2012-10-17
WO2005067927A3 (en)	2005-12-01
EP2279738A1 (en)	2011-02-02
US20160346265A1 (en)	2016-12-01
ES2372756T3 (es)	2012-01-26
JP2007517833A (ja)	2007-07-05
CN1905875B (zh)	2010-07-28
US9119844B2 (en)	2015-09-01
AU2005205066B2 (en)	2010-04-29
JP5597179B2 (ja)	2014-10-01
EP1713480B1 (en)	2011-09-14
US20110245297A1 (en)	2011-10-06
EP1713480A2 (en)	2006-10-25
US20080207702A1 (en)	2008-08-28
US20140296305A1 (en)	2014-10-02
PL364348A1 (pl)	2005-07-25
ATE524179T1 (de)	2011-09-15
CN1905875A (zh)	2007-01-31
US9675601B2 (en)	2017-06-13
US20100173956A1 (en)	2010-07-08
AU2005205066C1 (en)	2010-08-26
US7935717B2 (en)	2011-05-03
US20150133508A1 (en)	2015-05-14
CA2547234C (en)	2010-07-20
DK1713480T3 (da)	2012-01-16
RU2366420C2 (ru)	2009-09-10
AU2005205066A1 (en)	2005-07-28
US8969391B2 (en)	2015-03-03
JP2012072150A (ja)	2012-04-12
PT1713480E (pt)	2011-11-28

Publication	Publication Date	Title
PL364348A1 (pl)	2005-07-25	Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
AP2002002637A0 (en)	2002-09-30	Novel piperazine
CY1109925T1 (el)	2014-09-10	Η χρηση πυριδυλ αμιδιων ως παρεμποδιστων της αγγειογενεσης
SI2238982T1 (sl)	2013-01-31	Terapevtsko sredstvo za mehkotkivni sarkom
TW200728307A (en)	2007-08-01	Novel spirochromanone derivatives
TW200635582A (en)	2006-10-16	Medicaments for the treatment or prevention of fibrotic diseases
PT1259489E (pt)	2006-08-31	Compostos azapoliciclicos condensados con arilo.
TW200642685A (en)	2006-12-16	Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
IL166298A0 (en)	2006-01-15	8-hydroxy quinoline derivatives
AU2134402A (en)	2002-07-01	Antiviral agents
TR200402656T4 (tr)	2004-11-22	Antikanser ajanları olarak faydalı tiyofen türevleri
TWI265928B (en)	2006-11-11	A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
TW200420549A (en)	2004-10-16	Thiazole derivatives
PT1513519E (pt)	2009-05-06	Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
WO2002051832A3 (en)	2002-09-06	Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
AP2001002306A0 (en)	2001-12-31	Bridged piperazine derivatives.
EE200000298A (et)	2001-08-15	Bifenüülamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning profülaktiline ja terapeutiline toimeaine tromboosi või emboolia vastu
BR0312798A (pt)	2005-05-03	Derivados de isotiazol úteis como agentes anticancerìgenos
TW200635594A (en)	2006-10-16	Phenyl-piperazin methanone derivatives
ATE340575T1 (de)	2006-10-15	Vorbeugung und behandlung von krankheiten in zusammenhang zu vaskularen funktionellen stoerungen un verbindung mit insulinresistenz
MY139586A (en)	2009-10-30	Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives for reducing ichaemic damage
TW200640462A (en)	2006-12-01	Compounds
WO2006050861A3 (en)	2006-08-10	Statine derivatives for the treatment of alzheimer's disease
TW200714593A (en)	2007-04-16	Agent for treatment of solid tumor
WO2006031719A3 (en)	2006-09-14	1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof